Ibrexafungerp (Brexafemme) for Vulvovaginal Candidiasis

The FDA has approved ibrexafungerp (Brexafemme –
Scynexis), a first-in-class triterpenoid antifungal
(“fungerp”), for oral treatment of vulvovaginal candidiasis
in postmenarchal females.